NCT06029179View on ClinicalTrials.gov

SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

October 15, 2024

Study Completion Date

December 15, 2024

Conditions
Hyperkalemia
Interventions
DRUG

sodium zirconium cyclosilicate (SZC)

60 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 8 weeks.

DRUG

sodium polystyrene sulfonate

60 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 8 weeks.

Trial Locations (1)

21526

Faculty of Medicine, Aexandria University, Alexandria

All Listed Sponsors
lead

Alexandria University

OTHER

NCT06029179 - SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients | Biotech Hunter | Biotech Hunter